CN114127087A - Actrii结合蛋白及其用途 - Google Patents

Actrii结合蛋白及其用途 Download PDF

Info

Publication number
CN114127087A
CN114127087A CN202080051148.1A CN202080051148A CN114127087A CN 114127087 A CN114127087 A CN 114127087A CN 202080051148 A CN202080051148 A CN 202080051148A CN 114127087 A CN114127087 A CN 114127087A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
actrii
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051148.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·库马尔
J·贝尔克
A·格林贝格
D·萨科
R·卡斯顿圭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CN114127087A publication Critical patent/CN114127087A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080051148.1A 2019-05-30 2020-05-29 Actrii结合蛋白及其用途 Pending CN114127087A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CN114127087A true CN114127087A (zh) 2022-03-01

Family

ID=73553540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051148.1A Pending CN114127087A (zh) 2019-05-30 2020-05-29 Actrii结合蛋白及其用途

Country Status (8)

Country Link
US (1) US12545736B2 (https=)
EP (1) EP3976630A4 (https=)
JP (2) JP7669291B2 (https=)
KR (1) KR20220029563A (https=)
CN (1) CN114127087A (https=)
AU (1) AU2020284038A1 (https=)
CA (1) CA3142149A1 (https=)
WO (1) WO2020243448A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121344183A (zh) * 2025-12-18 2026-01-16 成都医学院 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
JP2024532345A (ja) * 2021-09-03 2024-09-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 抗ａｃｖｒ２ａ抗体及びその使用
AU2024317572A1 (en) 2023-07-31 2026-03-12 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025026353A1 (en) * 2023-08-01 2025-02-06 Laekna Therapeutics Shanghai Co., Ltd. Anti-acvr2b antibodies and uses thereof
WO2025068454A1 (en) * 2023-09-28 2025-04-03 Sixpeaks Bio Ag Antibodies targeting actriia and actriib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234106A1 (en) * 2006-09-08 2009-09-17 Amgen Inc. Anti-activin a antibodies and uses thereof
US20130108650A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
US20150037339A1 (en) * 2013-07-30 2015-02-05 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and uses thereof
US20170281711A1 (en) * 2016-03-10 2017-10-05 Acceleron Pharma Inc. Activin Type 2 Receptor Binding Proteins and Uses Thereof
CN107683287A (zh) * 2015-04-22 2018-02-09 奥健美国公司 用于治疗肌肉萎缩疾病的新型杂合actriib配体陷阱蛋白
WO2018175460A1 (en) * 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
AU2017222526A1 (en) 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234106A1 (en) * 2006-09-08 2009-09-17 Amgen Inc. Anti-activin a antibodies and uses thereof
US20130108650A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
US20150037339A1 (en) * 2013-07-30 2015-02-05 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and uses thereof
CN107683287A (zh) * 2015-04-22 2018-02-09 奥健美国公司 用于治疗肌肉萎缩疾病的新型杂合actriib配体陷阱蛋白
US20170281711A1 (en) * 2016-03-10 2017-10-05 Acceleron Pharma Inc. Activin Type 2 Receptor Binding Proteins and Uses Thereof
CN109153713A (zh) * 2016-03-10 2019-01-04 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
WO2018175460A1 (en) * 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LACH-TRIFILIEFF等: "An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy", MOLECULAR AND CELLULAR BIOLOGY, vol. 34, no. 04, pages 606 - 618, XP055254997, DOI: 10.1128/MCB.01307-13 *
MORVAN等: "Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy", PNAS, vol. 114, no. 47, pages 12448 - 12453, XP055478440, DOI: 10.1073/pnas.1707925114 *
龚凤英等: "活化素抑制大鼠垂体GH_3细胞中人生长激素基因启动子的活性", 生理学报, vol. 62, no. 01, pages 49 - 54 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121344183A (zh) * 2025-12-18 2026-01-16 成都医学院 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途

Also Published As

Publication number Publication date
EP3976630A4 (en) 2024-03-20
WO2020243448A1 (en) 2020-12-03
KR20220029563A (ko) 2022-03-08
JP2025118664A (ja) 2025-08-13
WO2020243448A8 (en) 2022-05-05
JP2022534966A (ja) 2022-08-04
US12545736B2 (en) 2026-02-10
JP7669291B2 (ja) 2025-04-28
EP3976630A1 (en) 2022-04-06
US20220242956A1 (en) 2022-08-04
CA3142149A1 (en) 2020-12-03
AU2020284038A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CN114127087A (zh) Actrii结合蛋白及其用途
JP7469284B2 (ja) アクチビン２型受容体結合タンパク質及びその使用
CN109219446B (zh) Alk7结合蛋白及其用途
JP7075135B2 (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
CN114245805A (zh) Alk7结合蛋白及其用途
HK40095415A (zh) 活化素2型受体结合蛋白及其用途
HK40002449A (en) Activin type 2 receptor binding proteins and uses thereof
HK40003020A (en) Alk7 binding proteins and uses thereof
HK40003457B (en) Activin type 2 receptor binding proteins and uses thereof
HK40003457A (en) Activin type 2 receptor binding proteins and uses thereof
HK40002449B (en) Activin type 2 receptor binding proteins and uses thereof
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination